|
|
| |
|
| The
cervical cancer SPORE program will improve the clinical care
of patients with cervical cancer to a much greater degree
than the efforts of the individual researchers working
separately. |
|
|
|
|
|
Cancerous cells
CERVICAL CANCER FACTS
Approximately 500,000 women worldwide develop cervical
cancer each year and it is the second leading cause of
cancer death in women. Despite well-established cervical
cancer screening programs, the incidence of invasive
cervical cancer in the US has been increasing at a rate
of 3% per year since 1986 (SEER Cancer Statistics
Review). Thus, cervical cancer continues to be a
major health care problem in the U.S. and worldwide.
See more
|
|
|
| |
CLINICAL TRIALS
Although the most
potent responses to vaccination in our preclinical model
were obtained using gene gun vaccination, this technology
was not available for clinical use. Therefore, we compared
responses to immunization with clinical grade vaccine via
three different routes
See more
|
|
NTEGRATION
SPORE Interactions and
Collaborations
The Cervical Cancer
SPORE is a highly interactive and multidisciplinary program
incorporating six projects and three cores. The relationships
that exist among the many participating investigators have resulted
in productive developments and opportunities, as demonstrated by
joint authored research articles, cooperation on grants, and
translational application of some research developments in clinical
trials. Investigators are frequently involved in more than one
project, demonstrating the extent of collaborations between
investigators across several project areas
|
|
|
|
|
Plasmid
DNA encoding HSP70 protein linked to a detoxified version of
HPV-16 E7 antigen to enhance vaccine potency
Enlarge
picture |
|
CLINICAL TRANSLATION
SPORE Interactions and
Collaborations
The diversity of our
translational research objectives is reflected by the focus
of each project on different targets throughout the disease
process. The SPORE program incorporates translational
research in 3 major program areas – Program 1: Molecular
Markers Relevant to the Screening, Diagnosis, and Prognosis
of Cervical Cancer (Projects 1 and 2), Program 2: Preventive
Vaccines for Cervical Cancer (Projects 3 and 4), and Program
3: Innovative Therapeutic Vaccines to Control HPV-Associated
Precursor Lesions (Project 5) and Advanced Cervical Cancer
(Project 6)
|
|
|
|
POPULATIONS
Rural India is the Site of
Study to Identify Markers of Progression to Cervical Cancer
In industrialized societies
where Pap smear screening was introduced in the 1950s, a
substantial reduction of cervical cancer incidence was
achieved. However, for a variety of reasons, effective
Pap smear programs have not been established and maintained
in areas of high cervical cancer incidence such as India,
Latin America and Africa. To address this issue, we
have included two projects (Projects 1 and 3) that focus on
geographic areas with a high prevalence of cervical cancer.
See more
|
|
|
NCI SPOREs
SPOREs
Overview
In 1992,
the NCI established the Specialized Programs of Research
Excellence (SPOREs) to promote interdisciplinary research
and to speed the bi-directional exchange between basic and
clinical science to move basic research finding from the
laboratory to applied settings involving patients and
populations.
The goal of the
SPORE program is to bring to clinical care settings novel
ideas that have the potential to reduce cancer incidence and
mortality, improve survival, and to improve the quality of
life. Laboratory and clinical scientists work
collaboratively to plan, design and implement research
programs that impact on cancer prevention, detection,
diagnosis, treatment and control.
|
|
|
|
|
ANNOUNCEMENT
|
Several
pilot project grants are now available to support new projects in advanced cervical cancer-related research.
Priority will be given to translational research projects, as
well as to projects related to the development of human
immunological assays against the human papillomavirus. Basic
research that has obvious, near-term potential application will also
be considered. Funds
for the pilot project program are provided by our NCI Cervical
Cancer SPORE grant.
See
the Guidelines for Submission
|
|
